Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.
Azmi Nabulsi net worth and biography

Azmi Nabulsi Biography and Net Worth

Azmi Nabulsi, M.D., is the former Deputy Chief Medical Officer, Chief Scientific Officer and Head of Global Development at Takeda Pharmaceuticals. In these roles, he led all global research and development, medical, regulatory, operations, and data analytics functions. In addition, he led research and development portfolio management strategy and planning, focusing on enhancing the company’s pipeline and productivity.

During his 14-year career at Takeda U.S. and Japan, Dr. Nabulsi oversaw global drug development for both early and late-stage product candidates, and he was responsible for bringing the majority of Takeda’s 21 new drugs in multiple therapeutic areas and countries to market. He was also responsible for the design and execution of the company’s major research and development transformation, utilizing industry-leading approaches to drive innovation. Dr. Nabulsi has led or directed partnerships and alliances in gastroenterology, oncology, immunology, cardiovascular medicine, and metabolism. Prior to Takeda, he held leadership positions at Abbott Laboratories, including Head of Immunology and Oncology Ventures.  He currently serves on the Board of ReAlta Life Sciences, Inc.

Dr. Nabulsi has an M.D. from Ain-Shams University in Cairo and an M.P.H. from the University of Minnesota.

What is Azmi Nabulsi's net worth?

The estimated net worth of Azmi Nabulsi is at least $9.71 million as of May 16th, 2022. Dr. Nabulsi owns 785,700 shares of Phathom Pharmaceuticals stock worth more than $9,711,252 as of January 30th. This net worth estimate does not reflect any other investments that Dr. Nabulsi may own. Additionally, Dr. Nabulsi receives a salary of $791,720.00 as COO at Phathom Pharmaceuticals. Learn More about Azmi Nabulsi's net worth.

How old is Azmi Nabulsi?

Dr. Nabulsi is currently 62 years old. There are 5 older executives and no younger executives at Phathom Pharmaceuticals. Learn More on Azmi Nabulsi's age.

What is Azmi Nabulsi's salary?

As the COO of Phathom Pharmaceuticals, Inc., Dr. Nabulsi earned a total compensation package of $4,321,236.00 in 2021. Dr. Nabulsi earned a salary of $491,250.00, options awards of $3,529,515.00, non-equity compensation of $285,846.00, and other compensation of $14,625.00.The highest earning executive at Phathom Pharmaceuticals is Ms. Terrie J. Curran, Pres, CEO & Director, who commands a salary of $978,380.00 per year. Learn More on Azmi Nabulsi's salary.

How do I contact Azmi Nabulsi?

The corporate mailing address for Dr. Nabulsi and other Phathom Pharmaceuticals executives is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. Phathom Pharmaceuticals can also be reached via phone at 877-742-8466 and via email at [email protected] Learn More on Azmi Nabulsi's contact information.

Has Azmi Nabulsi been buying or selling shares of Phathom Pharmaceuticals?

Azmi Nabulsi has not been actively trading shares of Phathom Pharmaceuticals during the last quarter. Most recently, on Monday, May 16th, Azmi Nabulsi bought 20,000 shares of Phathom Pharmaceuticals stock. The stock was acquired at an average cost of $8.16 per share, with a total value of $163,200.00. Following the completion of the transaction, the chief operating officer now directly owns 785,700 shares of the company's stock, valued at $6,411,312. Learn More on Azmi Nabulsi's trading history.

Who are Phathom Pharmaceuticals' active insiders?

Phathom Pharmaceuticals' insider roster includes Terrie Curran (Insider), Azmi Nabulsi (COO), and David Socks (Director). Learn More on Phathom Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Phathom Pharmaceuticals?

During the last year, Phathom Pharmaceuticals insiders bought shares 4 times. They purchased a total of 58,000 shares worth more than $450,105.00. During the last year, insiders at the sold shares 2 times. They sold a total of 5,839 shares worth more than $48,074.20. The most recent insider tranaction occured on January, 20th when insider Terrie Curran sold 5,821 shares worth more than $47,732.20. Insiders at Phathom Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Phathom Pharmaceuticals.

Information on this page was last updated on 1/20/2023.

Azmi Nabulsi Insider Trading History at Phathom Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2022Buy20,000$8.16$163,200.00785,700View SEC Filing Icon  
5/3/2021Sell10,043$38.27$384,345.61View SEC Filing Icon  
4/5/2021Sell9,353$36.11$337,736.83View SEC Filing Icon  
4/1/2021Sell5,147$37.57$193,372.79View SEC Filing Icon  
3/1/2021Sell5,373$45.85$246,352.05View SEC Filing Icon  
12/1/2020Sell7,198$44.20$318,151.60View SEC Filing Icon  
11/2/2020Sell14,500$36.83$534,035.00View SEC Filing Icon  
See Full Table

Azmi Nabulsi Buying and Selling Activity at Phathom Pharmaceuticals

This chart shows Azmi Nabulsi's buying and selling at Phathom Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Phathom Pharmaceuticals Company Overview

Phathom Pharmaceuticals logo
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Read More

Today's Range

Now: $12.36
Low: $11.36
High: $13.44

50 Day Range

MA: $9.85
Low: $7.31
High: $12.36

2 Week Range

Now: $12.36
Low: $6.09
High: $19.95


521,200 shs

Average Volume

506,106 shs

Market Capitalization

$514.42 million

P/E Ratio


Dividend Yield



Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.